ArticleJournal of bacteriology2006
Genetic variation in the Vibrio vulnificus group 1 capsular polysaccharide operon.
Article in Journal of bacteriology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 97 citations in OpenAlex.
- Emergence, climate-driven expansion, and diversification of a EuropeanEmerging microbes & infections · 2026Article
- Rapid Detection ofMicroorganisms · 2026Article
- Maximizing bacterial survival: integrating sense-and-respond and bet-hedging mechanisms.Trends in microbiology · 2025Review
- Proteome-wide bioinformatic annotation and functional validation of the monotopic phosphoglycosyl transferase superfamily.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Proteome-Wide Bioinformatic Annotation and Functional Validation of the Monotopic Phosphoglycosyl Transferase Superfamily.bioRxiv : the preprint server for biology · 2024Article
- Effect of capsular polysaccharide phase variation on biofilm formation, motility and gene expression in Vibrio vulnificus.Gut pathogens · 2024Article
- Article
- Prevalence, Genetic Diversity, Antimicrobial Resistance, and Toxigenic Profile ofAntibiotics (Basel, Switzerland) · 2021Article
- Exploring the Pathogenic Potential ofMicroorganisms · 2020Article
- Structure, Function, and Regulation of the Essential Virulence Factor Capsular Polysaccharide ofInternational journal of molecular sciences · 2020Review
- Comprehensive identification of Vibrio vulnificus genes required for growth in human serum.Virulence · 2018Article
- Vibrio vulnificus in aquariums is a novel threat to marine mammals and public health.Transboundary and emerging diseases · 2018Article
- The Opportunistic PathogenFrontiers in microbiology · 2017Article
- Characterization of self-generated variants in Pseudoalteromonas lipolytica biofilm with increased antifouling activities.Applied microbiology and biotechnology · 2015Article
- The cabABC Operon Essential for Biofilm and Rugose Colony Development in Vibrio vulnificus.PLoS pathogens · 2015Article
- Role of anaerobiosis in capsule production and biofilm formation in Vibrio vulnificus.Infection and immunity · 2015Article
- Article
- Serum Survival of Vibrio vulnificus: Role of Genotype, Capsule, Complement, Clinical Origin, and in Situ Incubation.Pathogens (Basel, Switzerland) · 2014Article
- Genetic analysis and prevalence studies of the brp exopolysaccharide locus of Vibrio vulnificus.PloS one · 2014Article
- Molecular typing of environmental and clinical strains of Vibrio vulnificus isolated in the northeastern USA.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vibrio vulnificus produces human disease associated with raw-oyster consumption or wound infections, but fatalities are limited to persons with chronic underlying illness. Capsular polysaccharide (CPS) is required for virulence, and CPS expression correlates with opaque (Op) colonies that show "phase variation" to avirulent translucent (Tr) phenotypes with reduced CPS. The results discussed here confirmed homology of a V. vulnificus CPS locus to the group 1 CPS operon in Escherichia coli. However, two distinct V. vulnificus genotypes or alleles were associated with the operon, and they diverged at sequences encoding hypothetical proteins and also at unique, intergenic repetitive DNA elements. Phase variation was examined under conditions that promoted high-frequency transition of Op to Tr forms. Recovery of Tr isolates in these experiments showed multiple genotypes, which were designated TR1, TR2, and TR3: CPS operons of TR1 isolates were identical to the Op parent, and cells remained phase variable but expressed reduced CPS. TR2 and TR3 showed deletion mutations in one (wzb) or multiple genes, respectively, and deletion mutants were acapsular and locked in the Tr phase. Complementation in trans restored the Op phenotype in strains with the wzb deletion mutation. Allelic variation in repetitive elements determined the locations, rates, and extents of deletion mutations. Thus, different mechanisms are responsible for reversible phase variation in CPS expression versus genetic deletions in the CPS operon of V. vulnificus. Repetitive-element-mediated deletion mutations were highly conserved within the species and are likely to promote survival in estuarine environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.